Oral News and Research

RSS

China Aoxing submits an NDA to the China SFDA for its Codeine Phosphate

China Aoxing Pharmaceutical Company, Inc. (OTCBB: CAXG) ("China Aoxing"), a pharmaceutical company specializing in research, development, manufacturing and marketing of narcotic and pain-management products, today announced that it has submitted a new drug application (NDA) to the China State Food and Drug Administration (SFDA) for its Codeine Phosphate, a compound oral solution for the treatment of acute moderate to severe cough.

3 Sep 2009

Medtronic's COPE-HCV clinical study commences

Medtronic, Inc., today reported the initiation and first enrollments of patients in COPE-HCV (COntinuous Interferon Delivery via the Medtronic Paradigm Pump Infusion System Clinical Evaluation for Chronic HCV), the company’s first-ever clinical study using an external pump infusion system to treat patients with the hepatitis C virus (HCV).

3 Sep 2009

P2Y2 to be included in the intellectual property sale auction

Joseph F. Finn, Jr., C.P.A. ("Finn"), announced today that the P2Y2 Gastrointestinal Early Development Candidate Program will be part of the intellectual property offered for sale at the September 30, 2009 auction.

3 Sep 2009

Study reports a potential new investigational therapy for skin cancer

A study published today in the New England Journal of Medicine reports a potential new investigational therapy for advanced and metastatic basal cell skin cancer tested at the Virginia G. Piper Cancer Center at Scottsdale Healthcare and other sites appears to demonstrate tumor shrinkage and limited side effects in patients.

3 Sep 2009

Recurrence of Clostridium difficile infection is a growing area of concern in hospitals

Arlington Medical Resources (AMR) and Decision Resources find that relapse or recurrence of infections is the most challenging aspect of treating Clostridium difficile infections in the hospital setting.

3 Sep 2009

Biogen Idec's MS franchise to present at the 25th Congress of ECTRIMS

Biogen Idec today announced more than 70 platform and poster presentations from the company’s multiple sclerosis (MS) franchise being presented during the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Düsseldorf, Germany.

3 Sep 2009

Clinical trial results of sumatriptan published in a journal

NovaDel Pharma Inc. announced that an article titled “Rapid Oral Transmucosal Absorption of Sumatriptan, and Pharmacodynamics in Acute Migraine” was published online on June 22, 2009 in the peer-reviewed journal Headache: The Journal of Head and Face Pain.

3 Sep 2009

New online interactive quiz to gauge risk for cavities

Your risk for cavities can be gauged in minutes, thanks to a new interactive quiz launched today by a group of Delta Dental companies.

3 Sep 2009

GDC-0449 inhibits the Hedgehog signaling pathway

The Hedgehog signaling pathway is involved in a preliminary study and case report describing positive responses to an experimental anticancer drug in a majority of people with advanced or metastatic basal cell skin cancers. One patient with the most common type of pediatric brain cancer, medulloblastoma, also showed tumor shrinkage.

3 Sep 2009

New therapy for advanced and metastatic basal cell skin cancer

3 Sep 2009

Antibiotic used to treat trachoma reduces child mortality in Ethiopia, study finds

The antibiotic used to treat trachoma, "the world's leading preventable cause of blindness," may also protect children living in Ethiopia from death from of other diseases, according to a recent study, the Associated Press reports.

2 Sep 2009

Tips to prevent tooth decay in children

"Tooth decay can impact a child's ability to focus, learn and even attend class," says ODA President Dr. Ira Kirshen. "The good news is that it is entirely preventable. Parents can help children fight off tooth decay by simply teaching them good oral health habits."

2 Sep 2009

Validus chooses Ranbaxy to market an authorized generic version of Rocaltrol in the US

Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), Gurgaon, India, announced an agreement with Validus Pharmaceuticals LLC (Validus) to market and distribute an authorized generic version of Rocaltrol(R) (calcitriol) in both softgel capsules and an oral liquid formulation. Overall market sales for calcitriol softgel capsules and oral liquid were $70 million (IMS - MAT: June 2009).

2 Sep 2009

Education and cardiac defibrillators can boost survival rates

More widespread availability of defibrillators and education of the general public could boost survival rates fourfold amongst athletes suffering cardiac arrest, a study has found. In less than half of cases, a bystander initiated cardiopulmonary reanimation. This is crucial as survival at hospital admission is 4 times higher when CPR is attempted and 10 times greater when an electric shock is delivered.

2 Sep 2009

Eye disease medication lowers death rate among Ethiopian children

Children in Ethiopia who received the antibiotic azithromycin as a method for controlling the contagious eye disease trachoma had a lower odds of death compared to children who did not receive the antibiotic, according to a study in the September 2 issue of JAMA.

2 Sep 2009

Dr. Raman Bedi to exclusively represent Oragenics' oral care products

Florida-based biopharmaceutical leader Oragenics, Inc. has appointed renowned international oral care authority Dr. Raman Bedi to serve as exclusive representative for the company’s award-winning line of oral care products to the Middle East.

1 Sep 2009

Warfarin therapy provides substantial protection for elder patients with atrial fibrillation

Warfarin (an oral anticoagulant) therapy for patients with atrial fibrillation - the most common type of significant heart rhythm disorder - appears to be most beneficial for the oldest patients, for those who have had a prior stroke and for patients with multiple risk factors for stroke, according to a new study by Kaiser Permanente and Massachusetts General Hospital researchers.

1 Sep 2009

Results of the first pivotal Phase III trial with pimavanserin in patients with PDP announced

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from the first pivotal Phase III trial with pimavanserin in patients with Parkinson’s disease psychosis, or PDP. The study did not meet its primary endpoint of antipsychotic efficacy as measured using the Scale for the Assessment of Positive Symptoms, or SAPS.

1 Sep 2009

Biovail announces Phase III trial results for pimavanserin

Biovail Corporation today announced top-line results from ACADIA Pharmaceutical Inc.’s first pivotal Phase III trial with pimavanserin in patients with Parkinson’s disease psychosis, or PDP.

1 Sep 2009

LTS LOHMANN Therapie-Systeme celebrates 25th anniversary

LTS LOHMANN Therapie-Systeme AG, the leading developer and manufacturer of transdermal, topical and oral systems with facilities in Andernach, Germany and West Caldwell, New Jersey, celebrates its 25th anniversary.

1 Sep 2009